S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Pharmacyclics Receives 2014 Society for Medicines Research Award for Drug Discovery for Ibrutinib (IMBRUVICA®)|
|AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers|
|AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors|
|Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and Leukemia|
|Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia (CLL) Patients|
|Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration|
|Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia|
|Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results|
|Pharmacyclics Named 2014 Outstanding Company by BayBio|
|Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma|
Click above to view more mutual fund data and stats for pcyc - Pharmacyclics Inc.